Endocrine Abstracts

Introduction and objetives: There are few data in literature about the effects of rosuvastatin in patients with familial hypercholesterolemia in Spain. The objective of this study has been:

1-to evaluate the efficacy and security of rosuvastatin in patients with familiar hypercholesterolemia

2-to test the hypothesis that patients with diabetes have different response to treatment with rosuvastatin.

Material and methods: Descriptive study of patients followed in a Familial Dyslipidemia Unit, treated with rosuvastatin.

Results: Eighty-two patients with familial hipercholesterolemia. Mean age: 56.16±8.84 años.62,5% heterozygous familial hypercholesterolemia and 37.5% familial combined hyperlipidemia.Indication to initiate rosuvastatin: 68.8% non-achievement of objectives; 15.6% hepatic impairment with other statins, 12.5% patients polypharmacy(more risk of interaction) and 3.1% intolerance to other statins. Mean dose: 14.35±8.82 mg. 90.6% had previously statins, 59.4% ezetimibe and 31.3% fenofibrate.Average values of total cholesterol, LDL, HDL and TG before and after treatment were respectively (mg /dl): 245.75±67.44 vs 198.37±62.12(P 0, 000),decreased 19%, 159.62±62.36 vs 116.31±57.92 (P 0.000), decreased 27.5%, 41.8±10.29 vs 43.93±9.34 (P 0.36) and 309±475 vs 291±616 (P 0.76) Side effects were: 1 elevation of liver enzymes (less than twice normal values) and 3 patients had myalgia forcing to withdraw medication. Percentage of patients achieving LDL target were: 9,4% before vs 62,5% after rosuvastatin. Diabetic patients had a minor decrease in CT and LDL levels than non-diabetics: CT decrease 20.78± 22.57 in diabetic vs 66.26±28.55 in non diabetic (P 0.000) and decrease of LDL 17.57±25.01 vs 62.2±30.99 (P 0.000) respectively.

Conclusions: Rosuvastatin produced significant decrease in CT and LDL cholesterol in patients with familial dyslipidemia, without significant changes in TG and HDL. Patients with familial hypercholesterolemia and type two diabetes, had a significantly lower decrease in CT and LDL than patients without diabetes despite similar doses of rosuvastatin.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.